The DOI matches its Crossref record.
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Abstract
Background & Aims: Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long‐term entecavir therapy in reduction of the risk of hepatocellular carcinoma (HCC), cirrhotic events and mortality in a large group of CHB‐related cirrhosis patients. Methods: The C‐TEAM (Cirrhosis‐Taiwanese EntecAvir Multicenter) study was a nationwide, multicenter, retrospective–prospective cohort study in Taiwan. We enrolled treatment‐naïve patients with CHB‐related cirrhosis and baseline HBV‐DNA≥2000 IU/mL receiving long‐term entecavir therapy and compared the development of HCC, cirrhotic events and mortality with that of a historical untreated cohort. Results: In total, 1315 entecavir‐treated and 503 untreated patients with cirrhosis were enrolled, with median treatment and follow‐up durations of 4 and 6 years respectively. Compared with the untreated cohort, entecavir therapy was associated with a 60% HCC risk reduction [hazard ratio (HR): 0.40, 95% confidence interval (CI): 0.28‐0.57]. Additionally, an older age, the male gender, HBeA g positivity, alpha‐fetoprotein (AFP)≥7 ng/mL before therapy were independent predictors of HCC development. Further analysis showed that entecavir therapy significantly reduced risks of variceal bleeding, spontaneous bacterial peritonitis, and liver‐related and all‐cause mortality. These findings were confirmed by propensity score‐matched cohorts in sensitivity analysis. In patients under entecavir therapy, an older age, the male gender, HBeA g positivity, AFP level ≥7 ng/mL before therapy, and 1‐year virological response were predictive of HCC development. Conclusions: Four‐year entecavir therapy significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB‐related cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C.-L. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.35 · Cited by 814
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Papatheodoridis, G. V., Idilman, R., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Calleja, J. L., Sypsa, V., Goulis, J., Manolakopoulos, S., et al. (2017) · Hepatology · doi:10.1002/hep.29320 · Cited by 301
Metadata
- Authors
- Su, T., Hu, T., Chen, C., Huang, Y., Chuang, W., Lin, C., Wang, C., Su, W., Chen, M., Peng, C., Chien, R., Huang, Y., Wang, H., Lin, C., Yang, S., Chen, T., Mo, L., Hsu, S., Tseng, K., Hsieh, T., Suk, F., Hu, C., Bair, M., Liang, C., Lei, Y., Tseng, T., Chen, C., Kao, J., & the C‐TEAM study group and the Taiwan Liver Diseases Consortium
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2016-10-04
- Volume
- 36
- Issue
- 12
- Pages
- 1755-1764
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2519375936
- Cited by
- 223
- References
- 0
- FWCI
- 19.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. https://app.cochat.ai/papers/10.1111/liv.13253
- The paper
- Su, T., Hu, T., Chen, C., Huang, Y., Chuang, W., Lin, C., Wang, C., Su, W., Chen, M., Peng, C., Chien, R., Huang, Y., Wang, H., Lin, C., Yang, S., Chen, T., Mo, L., Hsu, S., Tseng, K., . . . the C‐TEAM study group and the Taiwan Liver Diseases Consortium. (2016). Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver International. https://doi.org/10.1111/liv.13253
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.